Pharmacophore mapping-based virtual screening followed by molecular docking studies in search of potential acetylcholinesterase inhibitors as anti-Alzheimer's agents

BioSystems

Volumn 116, Issue 1, 2014, Pages 10-20

  Ambure, Pravin ^a   Kar, Supratik ^a   Roy, Kunal ^a  

^a JADAVPUR UNIVERSITY   (India)

Author keywords

Acetylcholinesterase inhibitor; Alzheimer's disease; Molecular docking; Pharmacophore mapping; QSAR; Virtual screening

Indexed keywords

CHOLINESTERASE INHIBITOR; COUMARIN DERIVATIVE; DONEPEZIL; NATURAL PRODUCT;

DRUG; ENZYME ACTIVITY; INHIBITOR; MOLECULAR ANALYSIS; NERVOUS SYSTEM DISORDER;

ALZHEIMER DISEASE; ARTICLE; CALCULATION; CHEMICAL INTERACTION; COMPUTER MODEL; DRUG SCREENING; ENZYME INHIBITION; FILTER; MOLECULAR DOCKING; PHARMACOPHORE; VALIDATION PROCESS;

ACETYLCHOLINESTERASE INHIBITOR; ALZHEIMER'S DISEASE; MOLECULAR DOCKING; PHARMACOPHORE MAPPING; QSAR; VIRTUAL SCREENING;

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; MOLECULAR DOCKING SIMULATION; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84890894521     PISSN: 03032647     EISSN: 18728324     Source Type: Journal    
DOI: 10.1016/j.biosystems.2013.12.002     Document Type: Article

References (46)

1. ADEAR (Alzheimer's Disease Education and Referral Center), 2013. http://www.nia.nih.gov/alzheimers/topics/alzheimers-basics.
2. Association A. Alzheimer's disease facts and figures. Alzheimers Dement. 2009, 5:234-270.
3. Awang K., Chan G., Litaudon M., Ismail N.H., Martin M.T., Gueritte F. 4-Phenylcoumarins from Mesua elegans with acetylcholinesterase inhibitory activity. Bioorg. Med. Chem. 2010, 18:7873-7877.
4. Axelsen P.H., Harel M., Silman I., Sussman J.L. Structure and dynamics of the active site gorge of acetylcholinesterase: synergistic use of molecular dynamics simulation and X-ray crystallography. Protein Sci. 1994, 3:188-197.
5. Babic T. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J. Neurol. Neurosurg. Psychiatry 1999, 67:558.
6. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database of Systematic Reviews 2006, (1). Art. No.: CD005593. 10.1002/14651858.CD005593.
7. Brooks B.R., Bruccoleri R.E., Olafson B.D., Swaminathan S., Karplus M. CHARMM: a program for macromolecular energy, minimization, and dynamics calculations. J. Comput. Chem. 2004, 4:187-217.
8. Clark J.K., Cowley P., Muir A.W., Palin R., Pow E., Prosser A.B., Taylor R., Zhang M.Q. Quaternary salts of E2020 analogues as acetylcholinesterase inhibitors for the reversal of neuromuscular block. Bioorg. Med. Chem. Lett. 2002, 12:2565-2568.
9. Corbeil C.R., Williams C.I., Labute P. Variability in docking success rates due to dataset preparation. J. Comput. Aided Mol. Des. 2012, 26:775-786.
10. Discovery Studio Version 2.1 2012, Accelrys Inc., San Diego, CA. http://www.accelrys.com/.
11. Fisher R.A. The design of experiments 1971, Macmillan. Ninth ed.
12. Ghose A.K., Viswanadhan V.N., Wendoloski J.J. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. J. Comb. Chem. 1999, 1:55-68.
13. Greenblatt H.M., Kryger G., Lewis T., Silman I., Sussman J.L. Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3Å resolution. FEBS Lett. 1999, 463:321-326.
14. Guo L., Suarez A.I., Braden M.R., Gerdes J.M., Thompson C.M. Inhibition of acetylcholinesterase by chromophore-linked fluorophosphonates. Bioorg. Med. Chem. Lett. 2010, 20:1194-1197.
15. Halgren T.A. Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94. J. Comput. Chem. 1998, 17:490-519.
16. Harel M., Schalk I., Ehret-Sabatier L., Bouet F., Goeldner M., Hirth C., Axelsen P.H., Silman I., Sussman J.L. Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. Proc. Natl. Acad. Sci. 1993, 90:9031-9035.
17. Inestrosa N.C., Alvarez A., Perez C.A., Moreno R.D., Vicente M., Linker C., Casanueva O.I., Soto C., Garrido J. Acetylcholinesterase accelerates assembly of amyloid-β-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron 1996, 16:881-891.
18. InterBioScreen's Natural Compound (NC) database 2012, http://www.ibscreen.com/natural.shtml.
19. Kar S., Roy K. First report on predictive chemometric modeling, 3D-toxicophore mapping and in silico screening of in vitro basal cytotoxicity of diverse organic chemicals. Toxicol. In Vitro 2012, 27:597-608.
20. ®): implications for the design of new anti-Alzheimer drugs. Structure 1999, 7:297-307.
21. Kryger G., Harel M., Giles K., Toker L., Velan B., Lazar A., Kronman C., Barak D., Ariel N., Shafferman A. Structures of recombinant native and E202Q mutant human acetylcholinesterase complexed with the snake-venom toxin fasciculin-II. Acta Crystallogr. D: Biol. Crystallogr. 2000, 56:1385-1394.
22. Lee J.H., Lee K.T., Yang J.H., Baek N.I., Kim D.K. Acetylcholinesterase inhibitors from the twigs of Vaccinium oldhami Miquel. Arch. Pharm. Res. 2004, 27:53-56.
23. Li H., Sutter J., Hoffmann R. HypoGen: an automated system for generating 3D predictive pharmacophore models. Pharmacophore Perception, Development, and Use in Drug Design. 2 2000, 171.
24. Lipinski C.A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 2000, 44:235-249.
25. Lu S.H., Wu J.W., Liu H.L., Zhao J.H., Liu K.T., Chuang C.K., Lin H.Y., Tsai W.B., Ho Y. The discovery of potential acetylcholinesterase inhibitors: a combination of pharmacophore modeling, virtual screening, and molecular docking studies. J. Biomed. Sci. 2011, 18:8.
26. Margarita D., Juan S., Rodrigo Q., Juan G., Macarena A., Nibaldo I. Amyloid-β-acetylcholinesterase complexes potentiate neurodegenerative changes induced by the Aβ peptide. Implications for the pathogenesis of Alzheimer's disease. Mol. Neurodegener. 2010, 5:4.
27. Martinez A., Castro A. Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer's disease. Expert Opin. Investig. Drugs 2006, 15:1-12.
28. Mattson M.P. Pathways towards and away from Alzheimer's disease. Nature 2004, 430:631-639.
29. Minati L., Edginton T., Grazia B.M., Giaccone G. Reviews: current concepts in Alzheimer's disease: a multidisciplinary review. Am. J. Alzheimers Dis. 2009, 24:95-121.
30. Molecular Operating Environment (MOE), 2012. Chemical Computing Group Inc., 1010, Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7. http://www.chemcomp.com/.
31. Nadri H., Pirali-Hamedani M., Shekarchi M., Abdollahi M., Sheibani V., Amanlou M., Shafiee A., Foroumadi A. Design, synthesis and anticholinesterase activity of a novel series of 1-benzyl-4-((6-alkoxy-3-oxobenzofuran-2 (3H)-ylidene) methyl) pyridinium derivatives. Bioorg. Med. Chem. 2010, 18:6360-6366.
32. QikProp Version 3.2 2012, Schrodinger, LLC, New York, NY 642. http://www.%20schrodinger.com/.
33. Raves M.L., Harel M., Pang Y.P., Silman I., Kozikowski A.P., Sussman J.L. Structure of acetylcholinesterase complexed with the nootropic alkaloid, (-)-huperzine A. Nat. Struct. Biol. 1997, 4:57-63.
34. Rella M., Rushworth C.A., Guy J.L., Turner A.J., Langer T., Jackson R.M. Structure-based pharmacophore design and virtual screening for novel angiotensin converting enzyme 2 inhibitors. J. Chem. Inf. Model. 2006, 46:708-716.
35. Sakkiah S., Thangapandian S., John S., Lee K.W. Pharmacophore based virtual screening, molecular docking studies to design potent heat shock protein 90 inhibitors. Eur. J. Med. Chem. 2011, 46:2937-2947.
36. Samadi A., Estrada M., Perez C., Rodriguez-Franco M.I., Iriepa I., Moraleda I., Chioua M., Marco-Contelles J. Pyridonepezils, new dual AChE inhibitors as potential drugs for the treatment of Alzheimer's disease: synthesis, biological assessment, and molecular modeling. Eur. J. Med. Chem. 2012, 57:296-301.
37. Saxena S., Chaudhaery S.S., Varshney K., Saxena A.K. Pharmacophore-based virtual screening and docking studies on Hsp90 inhibitors. SAR QSAR Environ. Res. 2010, 21:445-462.
38. Scarpini E., Scheltens P., Feldman J. Treatment of Alzheimer's disease: current status and new perspectives. Lancet Neurol. 2003, 2:539.
39. Smellie A., Teig S.L., Towbin P. Poling: promoting conformational variation. J. Comput. Chem. 1995, 16:171-187.
40. SPSS Inc. SPSS Version 9 2011, SPSS Inc., Chicago, IL, USA. http://www.spss.com/.
41. Sun H. Pharmacophore-based virtual screening. Curr. Med. Chem. 2008, 15:1018-1024.
42. Sussman J.L., Harel M., Frolow F. Atomic structure of acetylcholinesterase from Torpedo californica: a prototype acetylcholine binding protein. Science 1991, 253:872-879.
43. Tariot P.N., Federoff H.J. Current treatment for Alzheimer disease and future prospects. Alzheimer Dis. Assoc. Disord. 2003, 17:S105-S113.
44. Wimo A., Prince M.J. World Alzheimer Report 2010: the global economic impact of dementia, Alzheimer's Disease International 2010.
45. Yan A., Wang K. Quantitative structure and bioactivity relationship study on human acetylcholinesterase inhibitors. Bioorg. Med. Chem. Lett. 2012, 22:3336-3342.
46. Youkwan J., Sutthivaiyakit S., Sutthivaiyakit P. Citrusosides A-D and furanocoumarins with cholinesterase inhibitory activity from the fruit peels of citrus hystrix. J. Nat. Prod. 2010, 73:1879-1883.